Partnered program update
Posted: 1 August 2023 Following communication from AstraZeneca on Friday, 28 July 2023, and the subsequent release of AstraZeneca’s H1 and Q2 2023 results announcement that day, Starpharma (ASX: SPL, OTCQX: SPHRY) reports that AstraZeneca has made the…
First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
Posted: 1 August 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the first patient has been enrolled and safely dosed in…
Scientific breakthrough harnesses mRNA technology to develop powerful malaria vaccine
Posted: 1 August 2023 A new mRNA vaccine targeting immune cells in the liver could be the key to tackling malaria, a disease that causes over half a million deaths each year according to the World Health Organization,…
Advanced Cell Therapy Manufacturing Initiative to be established in Brisbane
Posted: 1 August 2023 CCRM Australia, with its Canadian partners OmniaBio Inc. and Toronto-based CCRM, has signed a Letter of Intent with The University of Queensland to establish the Advanced Cell Therapy Manufacturing Initiative (ACTMI) at the St…
Adherium Enteres Rapid US Commercialisation Phase
Posted: 1 August 2023 Adherium Limited (ASX: ADR), a leading provider of respiratory eHealth, remote monitoring and data management solutions, today announced it is entering a rapid commercialisation phase in reimbursed remote patient monitoring in the globally significant…
Advertising of Health Services – New Advertising Guidelines – Is your advertising compliant?
Posted: 31 July 2023 “This article provides an update on the new Medical Board/AHPRA “Guidelines For Registered Medical Practitioners who Advertise Cosmetic Surgery” which came into effect on 1 July 2023. Health practitioners, individuals, businesses, and companies involved…
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
Posted: 27 July 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) recommended the ATH434-201…
Certification paves the way for improved translational research
Posted: 27 July 2023 The Burnet Diagnostics Initiative (BDI) has reached a major milestone, having recently been awarded ISO 9001 certification. It is a significant step forward for the BDI, which has a strong focus on translational research, including developing…
Expanded Cell and Gene Therapy Manufacturing Facility Opens at Peter Mac
Posted: 27 July 2023 Australia’s only biomedical manufacturing site where CAR T-cells and other “living” cancer therapies can be made at commercial scale has expanded to meet future patient demand. Federal Minister for Health and Aged Care, the…
New Commercial-Scale Cell and Gene Therapy Manufacturing Facility for APAC Market Supply
Posted: 27 July 2023 Cell Therapies Pty Ltd. is excited to announce the opening of new cell and gene therapy GMP manufacturing facilities to meet future patient demand at the Peter MacCallum Cancer Centre. As Australia’s only biomedical…
BioCurate Announces Strategic Alliance with the Experimental Drug Development Centre in Singapore
Posted: 27 July 2023 Partnership will see co-investment and collaboration to advance promising biomedical research. BioCurate, an independently operated joint venture between the University of Melbourne and Monash University, announced today it has signed a Memorandum of Understanding…
Research to merge human brain cells with AI secures prestigious grant funding
Posted: 27 July 2023 Monash University-led research into growing human brain cells onto silicon chips, with new continual learning capabilities to transform machine learning, has been awarded almost $600,000 AUD in the prestigious National Intelligence and Security Discovery…
